Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
D01AE24
|
| gptkbp:CASNumber |
164650-44-6
|
| gptkbp:chemicalClass |
triazole antifungal
|
| gptkbp:concentration |
10%
|
| gptkbp:form |
gptkb:government_agency
|
| gptkbp:genericName |
gptkb:efinaconazole
|
| gptkbp:hasMolecularFormula |
C18H22F2N4O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jublia
|
| gptkbp:indication |
fungal nail infection
|
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
inhibits fungal lanosterol 14α-demethylase
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
application site dermatitis
blistering ingrown toenail pain at application site |
| gptkbp:synonym |
gptkb:efinaconazole_topical_solution
|
| gptkbp:usedFor |
treatment of onychomycosis
|
| gptkbp:bfsParent |
gptkb:Bausch_Health_Companies
gptkb:Valeant_Pharmaceuticals |
| gptkbp:bfsLayer |
6
|